Edwards Lifesciences - EW Stock Forecast, Price & News

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $104.74 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.37 and a quick ratio of 2.60. Edwards Lifesciences has a 1-year low of $85.58 and a 1-year high of $131.73. The firm has a market capitalization of $64.93 billion, a P/E ratio of 45.34, a price-to-earnings-growth ratio of 3.09 and a beta of 1.12. The company's 50-day moving average is $97.97 and its 200 day moving average is $105.03.

Edwards Lifesciences (NYSE:EW - Get Rating) last posted its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing analysts' consensus estimates of $0.64 by ($0.01). Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The firm had revenue of $1.37 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same period last year, the company earned $0.64 earnings per share. The business's revenue for the quarter was down .2% compared to the same quarter last year. Research analysts forecast that Edwards Lifesciences will post 2.51 EPS for the current year.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Stifel Nicolaus decreased their target price on shares of Edwards Lifesciences from $128.00 to $115.00 in a research note on Monday, July 18th. Citigroup reduced their price objective on Edwards Lifesciences from $134.00 to $115.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th. Truist Financial reduced their price objective on Edwards Lifesciences from $140.00 to $120.00 and set a "buy" rating for the company in a research note on Wednesday, July 20th. Canaccord Genuity Group lowered Edwards Lifesciences from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Finally, StockNews.com raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Friday, August 5th. Three research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $126.19.

Insider Transactions at Edwards Lifesciences

In other news, CEO Michael A. Mussallem sold 19,875 shares of the firm's stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $86.96, for a total transaction of $1,728,330.00. Following the transaction, the chief executive officer now directly owns 157,353 shares of the company's stock, valued at $13,683,416.88. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, CEO Michael A. Mussallem sold 19,875 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $86.96, for a total transaction of $1,728,330.00. Following the transaction, the chief executive officer now directly owns 157,353 shares of the company's stock, valued at $13,683,416.88. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Bernard J. Zovighian sold 4,811 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $103.66, for a total transaction of $498,708.26. Following the transaction, the vice president now directly owns 21,247 shares in the company, valued at $2,202,464.02. The disclosure for this sale can be found here. Over the last three months, insiders have sold 100,937 shares of company stock valued at $9,738,239. 1.29% of the stock is currently owned by company insiders.